Methods for colistin testing What works and what does not? Erika Matuschek, Ph D EUCAST Development Laboratory, EDL

Similar documents
EUCAST Frequently Asked Questions. by author. Rafael Cantón Hospital Universitario Ramón y Cajal, Madrid, Spain EUCAST Clinical Data Coordinator

AST issues of polymyxins and their implications for the routine laboratory

Methods for AST: diffusion or dilution? (pro s en con s)

Why some tests are no longer recommended

What is new in EUCAST South Africa, May, Gunnar Kahlmeter EUCAST Technical Data Coordinator and Webmaster Sweden

(and breakpoint table, MIC and. by author. ESCMID Online Lecture Library. conventions) ECCMID 2011, Milan

Screening and detection of carbapenemases

The CLSI Approach to Setting Breakpoints

Reporting blood culture results to clinicians: MIC, resistance mechanisms, both?

Attachment 12 URGENT FIELD SAFETY REMOVAL FSCA3193. ETEST Ceftriaxone TXL32 (Ref , ) FOAM packaging

URGENT FIELD SAFETY NOTICE FSCA3193. Etest Ceftriaxone TXL32 (Ref , ) SPB Packaging

Comparision of Antibiotic Susceptibility Testing As Per CLSI and Eucast Guidelines for Gram Negative Bacilli

ESCMID Online Lecture Library. by author

Rapid susceptibility testing: new phenotypic and non-wgs genotypic approaches

Antifungal susceptibility testing: Which method and when?

Evaluation of Antibacterial Effect of Odor Eliminating Compounds

Received 30 March 2005; returned 16 June 2005; revised 8 September 2005; accepted 12 September 2005

Report on susceptibility of Salmonella serotypes in Belgium Vicky Jasson

Detecting Carbapenemase-Producing Enterobacteriaceae: why isn t there a single best method?

Guidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011

Discussion points CLSI M100 S19 Update. #1 format of tables has changed. #2 non susceptible category

Received 12 December 2010/Returned for modification 5 January 2011/Accepted 16 March 2011

Cefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010

RAPID COMMUNICATION. Maura S. de Oliveira, I Silvia Figueiredo Costa, II Ewerton de Pedri, II Inneke van der Heijden, II Anna Sara S.

Methodological and interpretative problems in antimicrobial susceptiblity tests of P. aeruginosa

Spectrum of vancomycin and susceptibility testing

Mupirocin Rationale for the EUCAST clinical breakpoints, version th July 2010

In-House Standardization of Carba NP Test for Carbapenemase Detection in Gram Negative Bacteria

Cefuroxime iv Rationale for the EUCAST clinical breakpoints, version th September 2010

ACCEPTED. Comparison of disk diffusion and agar dilution methods for erythromycin and

ResFinder 4.0: towards in silico antibiograms

Insert for Kit 98006/98010/ KPC/Metallo-B-Lactamase Confirm Kit KPC+MBL detection Kit KPC/MBL and OXA-48 Confirm Kit REVISION: DBV0034J

/01/$ DOI: /JCM Copyright 2001, American Society for Microbiology. All Rights Reserved.

Received 21 April 1997/Returned for modification 30 June 1997/Accepted 28 August 1997

NONFERMENTING GRAM NEGATIVE RODS. April Abbott Deaconess Health System Evansville, IN

Sensitive and specific Modified Hodge Test for KPC and metallo-beta-lactamase

Standardisation of testing for Carbapenemase Producing Organisms (CPO) in Scotland

Comparison of Minocycline Susceptibility Testing Methods for Carbapenem- Resistant Acinetobacter baumannii

Detecting CRE. what does one need to do?

EVALUATION OF METHODS FOR AMPC β-lactamase IN GRAM NEGATIVE CLINICAL ISOLATES FROM TERTIARY CARE HOSPITALS

Against Aerobic Gram-Negative Bacilli

Report on the Japanese Veterinary Antimicrobial Resistance Monitoring System

Carbapenem Disks on MacConkey agar as screening methods for the detection of. Carbapenem-Resistant Gram negative rods in stools.

S. aureus NCTC 6571, E. coli NCTC (antibiotic

Microbiology products. Liofilchem Chromatic

Laboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator

Ceftazidime-Avibactam and Aztreonam an interesting strategy to Overcome β- Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae

Antibiotic Usage Related to Microorganisms Pattern and MIC

Controversial Issues in Susceptibility Testing: Point/Counterpoint. April N. Abbott, PhD D(ABMM) Romney M. Humphries, PhD D(ABMM)

Scottish Microbiology and Virology Network. Carbapenemase producers: screening and the new Scottish AMR Satellite Reference Laboratory Service

Case Studies, or Verification Vignettes

Noelisa Montero, MPH. Epidemiologist Consultant. October 19, 2017 Connecticut Department of Public Health Healthcare Associated Infections Program

Prevalence of Extended Spectrum -Lactamases In E.coli and Klebsiella spp. in a Tertiary Care Hospital

North Carolina CRE Laboratory Task Force

COMPARATIVE ANTI MICROBIAL STUDY OF SHUDDHA KASISA AND KASISA BHASMA

Update zu EUCAST 2012 Cornelia Lass-Flörl

BACTERIOLOGY PROFICIENCY TESTING PROGRAM

Chapter 4. Anti-bacterial studies of PUFA extracts from Sardinella longiceps and Sardinella fimbriata. 4.1 Introduction

Table 1. Antifungal Breakpoints for Candida. 2,3. Agent S SDD or I R. Fluconazole < 8.0 mg/ml mg/ml. > 64 mg/ml.

CHAPTER 8 ANTIBACTERIAL ACTIVITY OF THE CRUDE ETHANOLIC EXTRACT AND THE ISOLATED COMPOUNDS FROM THE STEM OF COSTUS IGNEUS

Multicenter study of the prevalence and the resistance mechanisms of carbapenem-resistant Enterobacteriaceae (CPE) in Belgium in

Received 13 September 2006/Returned for modification 6 November 2006/Accepted 26 December 2006

MHSAL Guidelines for the Prevention and Control of Antimicrobial Resistant Organisms (AROs) - Response to Questions

Expert rules. for Gram-negatives

on November 3, 2018 by guest

Antimicrobial activity of Terminalia chebula

Investigation of in-vitro susceptibility of multidrugresistant Acinetobacter baumannii strains isolated from clinical specimens to tigecycline

Phenotypic detection of ESBLs and carbapenemases

Affinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

LABORATORY BASED DST FOR BEDAQUILINE AND INTRODUCTION IN COUNTRIES

The Antibiotic Resistance Laboratory Network

Correspondence should be addressed to Irene Burckhardt;

Susceptibilities of Nonfermenters Other than Pseudomonas aeruginosa

Update on CLSI and EUCAST

(multidrug-resistant Pseudomonas aeruginosa; MDRP)

Evaluation of CHROMagar msupercarba for the detection of carbapenemaseproducing Gram-negative organisms

1* 1. Vijaya S. Rajmane, Shivaji T. Mohite

In vitro screening of five local medicinal plants for antibacterial activity using disc diffusion method

Expert rules in antimicrobial susceptibility testing: State of the art

Journal of Infectious Diseases and

CHAPTER 2 MATERIALS AND MATHODS

Received 21 July 2008/Accepted 3 September 2008

Academic Perspective in. David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic resistance PHE

An evaluation of 2.0 McFarland Etest method for detection of heterogeneous vancomycin-intermediate Staphylococcus aureus

Detection of carbapenemases in Enterobacteriaceae: a challenge for diagnostic microbiological laboratories

First detection of the mcr-1 gene in Escherichia coli isolated from livestock between 2013

Antibacterial activity and mechanism of ZnO nanoparticles on C. jejuni

Resistance to linezolid in enterococci and staphylococci referred to the national reference laboratory

Adenium Biotech. Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes

Resistance among Streptococcus pneumoniae Clinical Isolates by Use of the E Test

Comparative Activity of Cefotaxime and Selected f3-lactam Antibiotics Against Haemophilus Influenzae and Aerobic Gram-Negative Bacilli

Steven D. Brown* and Maria M. Traczewski. The Clinical Microbiology Institute, 9725 SW Commerce Circle, Wilsonville, Oregon 97070

Mohammed Al-janabi and ZainabYaseen

Detection of NDM-1, VIM-1, KPC, OXA-48, and OXA-162 carbapenemases by MALDI- TOF mass spectrometry

Prof. Dr. K. Aruna Lakshmi (DEAN Academic Affairs) Dept. of Microbiology GITAM University Visakhapatnam. Under the Guidance of.

In Vitro Susceptibility Pattern of Cephalosporin- Resistant Gram-Negative Bacteria

Received 31 January 2011/Returned for modification 2 March 2011/Accepted 15 March 2011

Transcription:

Methods for colistin testing What works and what does not? Erika Matuschek, Ph D EUCAST Development Laboratory, EDL 3 rd joint meeting on AMR in Salmonella and Campylobacter, Copenhagen 7 April 2017

Antimicrobial susceptibility testing of colistin Broth microdilution (BMD) International reference method (ISO 20776-1) Agar dilution? Gradient tests? Etest, biomérieux MIC Test Strip (MTS), Liofilchem Disk diffusion??

AST of colistin dilution methods BMD (reference) Sulphate salts Standard polystyrene trays No additives or pre-treatment of plates See EUCAST Guidance Documents www.eucast.org/guidance_documents/ In-house prepared or commercial plates Agar dilution To be evaluated

AST of colistin diffusion methods Gradient tests? Poor correlation with reference BMD Warning on www.eucast.org Disk diffusion? Poor separation between resistant and susceptible isolates Problems probably related to poor diffusion of colistin in agar

6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 No of isolates 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 No of isolates No of isolates Results colistin disk diffusion Enterobacteriaceae, 50 isolates 18 16 14 12 10 8 6 4 2 0 Colistin 10 µg MIC (mg/l) 32 16 8 4 2 1 0.5 0.25 20 18 16 14 12 10 8 6 4 2 0 Colistin 25 µg MIC (mg/l) 32 16 8 4 2 1 0.5 0.25 Inhibition zone diameter (mm) Inhibition zone diameter (mm) Colistin 50 µg 25 MIC (mg/l) 20 32 15 16 8 10 4 2 5 1 0 0.5 0.25 Inhibition zone diameter (mm)

Colistin MIC distributions http://www.eucast.org/mic_distributions_and_ecoffs/ All distributions are recently reviewed Old distributions with P-80 (tween) removed Only non-truncated distributions included ECOFFs established for E. coli, K. pneumoniae and P. aeruginosa More data are needed for Acinetobacter and Salmonella Clinical breakpoints: S 2, R>2 mg/l Enterobacteriaceae, Pseudomonas spp. and Acinetobacter spp.

0.002 0.004 0.008 0.016 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 No of isolates EUCAST evaluation of colistin MIC methods 75 Gram-negative bacteria with varying colistin MICs (0.25-128 mg/l) 14 E. coli of which 10 mcr-1 positive 18 K. pneumoniae of which 1 mcr-1 positive 21 P. aeruginosa 22 Acinetobacter spp. 20 15 10 S 2 mg/l R>2 mg/l 5 0 MIC (mg/l)

EUCAST evaluation of colistin MIC methods BMD According to ISO 20776-1 and EUCAST/CLSI recommendations Frozen panels as reference Commercial freeze-dried panels Sensititre, MICRONAUT-S, MICRONAUT MIC Strip Gradient tests Etest Mueller-Hinton (MH) agar: Oxoid, BBL and MHE MIC Test Strip (MTS) Mueller-Hinton (MH) agar: Oxoid and BBL

Manual reading of MICs 96 well microtiter plate MICRONAUT MIC Strip

Typical gradient test result Etest Often very narrow ellipse with a dip MICs were read at the bottom of the ellipse according to the manufacturer's instructions MTS Often 0.5-1 dilution higher on the right side of the strip MICs were read at the higher value according to the manufacturer's instructions

Results Essential agreement for colistin MIC tests (no of MICs being within ± 1 dilution of reference MIC). Essential agreement (EA) Organism E. coli and K. pneumoniae (n=32) P. aeruginosa (n=21) Acinetobacter spp. (n=22) All isolates (n=75) Colistin MIC range 0.25-32 0.25-128 0.5-32 0.25-128 Sensititre custom plate 27 19 20 66 (96%) MICRONAUT-S 31 21 20 72 (96%) MICRONAUT MIC-Strip 31 21 22 74 (99%) Etest, Oxoid MH 27 13 13 53 (71%) Etest, BBL MH 20 11 1 32 (43%) Etest, MHE 24 9 2 35 (47%) MTS, Oxoid MH 19 12 9 40 (53%) MTS, BBL MH 24 12 13 49 (65%) * The total number of tests for calculation of EA was 28 for E. coli/k. pneumoniae and 19 for P. aeruginosa due to truncation at 0.25 and >32 mg/l. Essential agreement BMD: 96-99% Gradient tests: 43-71% (depending on MH agar used)

Results Categorical agreement for colistin MIC tests Organism Colistin MIC range (mg/l) E. coli and K. pneumoniae (n=32) P. aeruginosa (n=21) Acinetobacter spp. (n=22) All isolates (n=75) 0.25-32 0.25-128 0.5-32 0.25-128 Major Errors (ME) Very Major Errors (VME) Sensititre custom plate 1 1 2 4 MICRONAUT-S 2 1 3 6 MICRONAUT MIC-Strip 2 0 3 5 Etest, Oxoid MH 2 0 0 2 Etest, BBL MH 1 0 0 1 Etest, MHE 2 0 0 2 MTS, Oxoid MH 0 0 0 0 MTS, BBL MH 0 0 0 0 Sensititre custom plate 0 0 0 0 MICRONAUT-S 0 2 0 2 MICRONAUT MIC-Strip 0 2 0 2 Etest, Oxoid MH 0 6 6 12 Etest, BBL MH 1 7 7 15 Etest, MHE 0 5 4 9 MTS, Oxoid MH 6 6 4 16 MTS, BBL MH 5 6 7 18

Results Quality Control (QC) strains Colistin MIC (mg/l) Colistin MIC method Escherichia coli Pseudomonas aeruginosa Escherichia coli ATCC 25922 ATCC 27853 NCTC 13846** 0.125 0.25 0.5 1 2 0.25 0.5 1 2 4 2 4 8 Reference frozen panel 7 1 8 1 7 Sensititre custom plate 4 * 4 1 7 8 MICRONAUT-S 5 3 4 4 7 1 MICRONAUT MIC-Strip 1 6 1 8 2 6 Etest, Oxoid MH 2 5 7 8 Etest, BBL MH 12 4 8 8 Etest, MHE 7 3 4 5 3 MTS, Oxoid MH 6 1 2 5 8 MTS, BBL MH 1 6 4 3 8 * 0.25 mg/l ** mcr-1 positive QC target value Upper/lower limit Red text = MIC out of range EUCAST QC table v 7.0: For E. coli NCTC 13846, the colistin MIC target value is 4 mg/l and should only on occasion be 2 or 8 mg/l.

Sensititre Colistin reference MIC (mg/l) 0.25 0.5 1 2 4 8 16 32 64 128 0.25 2 3 0.5 9 1 1 2 8 2 5 5 4 2 1 7 8 1 3 2 3 16 5 5 1 32 5 4 64 1 Results Commercial BMD panels MICRONAUT-S MICRONAUT MIC Strip Colistin reference MIC (mg/l) Colistin reference MIC (mg/l) 0.25 0.5 1 2 4 8 16 32 64 128 0.25 0.5 1 2 4 8 16 32 64 128 0.125 0.125 1 0.25 1 1 0.25 6 0.5 1 10 1 0.5 1 6 2 1 2 7 1 2 10 2 1 8 1 2 2 4 2 2 4 4 5 4 4 7 8 2 3 5 4 8 1 1 7 3 16 2 6 1 16 9 3 32 3 2 32 1 2 64 2 1 64 1 128 128

Etest Oxoid MH MIC Test Strip Oxoid MH Results Gradient tests BBL MH BBL MH MHE Colistin reference MIC (mg/l) Colistin reference MIC (mg/l) Colistin reference MIC (mg/l) 0.25 0.5 1 2 4 8 16 32 64 128 0.25 0.5 1 2 4 8 16 32 64 128 0.25 0.5 1 2 4 8 16 32 64 128 0.06 1 0.125 1 2 11 5 2 1 1 12 4 1 0.25 1 2 2 1 2 2 2 2 1 1 0.5 13 6 2 2 3 1 8 1 2 2 1 7 3 1 1 1 9 3 1 1 1 1 1 1 1 3 2 1 1 2 1 1 2 2 1 1 2 1 1 4 2 6 3 6 1 1 7 3 4 2 8 3 5 8 2 2 1 1 1 1 2 2 1 3 3 16 2 1 1 1 1 32 1 64 128 Colistin reference MIC (mg/l) Colistin reference MIC (mg/l) 0.25 0.5 1 2 4 8 16 32 64 128 0.25 0.5 1 2 4 8 16 32 64 128 0.25 1 0.5 1 2 2 2 2 12 4 2 1 2 12 14 7 5 3 7 1 2 12 5 2 4 7 2 1 4 5 4 5 3 8 3 3 1 8 1 2 1 2 16 32 64 128

Salmonella spp. 28 isolates (DTU and SSI), gradient tests on Oxoid and BBL MH Etest Oxoid MH BBL MH COL BMD COL BMD 0.25 0,5 1 2 4 8 16 32 0.25 0,5 1 2 4 8 16 32 0,125 0,125 1 1 1 0,25 0,25 5 3 1 2 0,5 1 1 2 0,5 2 1 2 1 6 5 2 2 1 2 1 2 1 4 4 4 4 1 8 4 8 3 16 16 32 32 64 64 MIC Test Strip Oxoid MH BBL MH COL BMD COL BMD 0.25 0,5 1 2 4 8 16 32 0.25 0,5 1 2 4 8 16 32 0,125 0,125 0,25 0,25 0,5 0,5 1 1 1 1 5 6 2 4 1 6 5 2 5 2 1 1 2 3 4 4 3 4 1 4 8 8 16 1 16 32 32 64 64

Conclusions Correlation with reference MICs was good for all BMD methods. Gradient tests generally underestimated colistin MICs resulting in very major errors (false susceptibility). The poor performance of gradient tests could not be detected with QC strains.

Warning on www.eucast.org Disk diffusion cannot be used for AST of colistin. Currently available gradient tests underestimate colistin MIC values (and resistance) and should be avoided. Use BMD for AST of colistin, but perform extended quality control.

EUCAST recommendations for colistin QC Use both a susceptible strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) AND the colistin resistant E. coli NCTC 13846 (mcr-1 positive). For E. coli NCTC 13846, the colistin MIC target value is 4 mg/l and should only on occasion be 2 or 8 mg/l. EUCAST QC Tables v 7.0, 2017

Further work Additional BMD methods will be evaluated Colistin SensiTest (Liofilchem) UMIC (Biocentric)

Read more! Poster 161, ECCMID 2017 (available soon) www.eccmid.org http://www.eucast.org/presentations_and_stati stics/eucast_at_eccmid/ http://www.eucast.org/warnings/

Check the EUCAST website regularly for updates on methodology, QC ranges and breakpoints. www.eucast.org For questions and comments, please contact erika.matuschek@escmid.org or the EUCAST secretariat (see website).